R
Robert K. Oldham
Researcher at National Institutes of Health
Publications - 40
Citations - 2682
Robert K. Oldham is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 21, co-authored 40 publications receiving 2661 citations.
Papers
More filters
Journal ArticleDOI
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
William H. West,Kurt W. Tauer,John R. Yannelli,Gailen D. Marshall,Douglas W. Orr,Gary B. Thurman,Robert K. Oldham +6 more
TL;DR: The administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
Journal ArticleDOI
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.
Kenneth A. Foon,Stephen A. Sherwin,Paul G. Abrams,Dan L. Longo,Mehmet F. Fer,Henry C. Stevenson,Jeffrey J. Ochs,Gino C. Bottino,Carolyn S. Schoenberger,Jacob Zeffren,Elaine S. Jaffe,Robert K. Oldham +11 more
TL;DR: It is suggested that recombinant leukocyte A interferon may be an effective new therapy for some patients with low- and intermediate-grade non-Hodgkin's lymphoma.
Journal ArticleDOI
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.
Stephen A. Sherwin,James A. Knost,Seymour Fein,Paul G. Abrams,Kenneth A. Foon,Jeffrey J. Ochs,Carolyn S. Schoenberger,Annette E. Maluish,Robert K. Oldham +8 more
TL;DR: Objective evidence of antitumor activity was seen in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease, breast cancer, and melanoma, indicating that IFL-rA, the first genetically engineered biological response modifier available for testing in cancer patients, is biologically active in vivo.
Journal ArticleDOI
Radioimmunodetection of Cutaneous T-Cell Lymphoma with 111In-Labeled T101 Monoclonal Antibody
Jorge A. Carrasquillo,Paul A. Bunn,A.M. Keenan,James C. Reynolds,Robert W. Schroff,Kenneth A. Foon,M. H. Su,Adi F. Gazdar,James L. Mulshine,Robert K. Oldham +9 more
TL;DR: The studies suggest that imaging with [111In]T101 may be of value in identifying sites of cutaneous T-cell lymphoma, and the mechanism of localization appears to be related to binding to T cells, which can then carry the radioactivity to involved sites.
Journal ArticleDOI
Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia.
Kenneth A. Foon,Gino C. Bottino,Paul G. Abrams,Mehmet F. Fer,Dan L. Longo,Carolyn S. Schoenberger,Robert K. Oldham +6 more
TL;DR: The dose and schedule of recombinant leukocyte A interferon therapy tested in this study are not effective in previously treated patients with advanced chronic lymphocytic leukemia.